menu
    • menu
    [{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Secretome Therapeutics

    Menu

    Secretome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretome Doses First Patient in Phase 1 STM-01 Heart Failure Study

                            Details : STM-01 is an investigational, allogeneic neonatal cardiac progenitor cell (nCPC) therapy to improve cardiac function in patients with HFpEF and other inflammatory-driven cardiovascular diseases.

                            Product Name : STM-01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretome’s STM-01 gets FDA Fast Track for HFpEF Neonatal Cell Therapy

                            Details : STM-01 is an investigational, allogeneic neonatal cardiac progenitor cell (nCPC) therapy to improve cardiac function in patients with HFpEF and other inflammatory-driven cardiovascular diseases.

                            Product Name : STM-01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Secretome Therapeutics

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $20.4 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Secretome Raises $20.4M to Develop Therapies for Cardiomyopathy and Heart Failure

                            Details : The funding will enable Secretome to initiate clinical trials for its lead asset, STM-01 for the treatment of heart failure with preserved ejection fraction.

                            Product Name : STM-01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : STM-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $20.4 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth